Document Detail


Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis.
MedLine Citation:
PMID:  20723651     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In hypertension, angiotensin receptor blockers can augment regression of left ventricular (LV) hypertrophy. It is not known whether this also is the case after aortic valve replacement (AVR) for severe aortic stenosis (AS). To test the hypothesis that treatment with candesartan in addition to conventional treatment is able to augment LV and left atrial (LA) reverse remodeling in patients with AS undergoing AVR, we studied 114 patients scheduled for AVR. Patients were randomized to treatment with candesartan 32 mg 1 time/day or conventional therapy immediately after AVR. Patients were followed with echocardiographic evaluations 3, 6, and 12 months after surgery. Primary end point was change in LV mass index. At baseline and during follow-up no differences in systolic, diastolic, and pulse pressures were seen between groups. Baseline LV mass index was 134 +/- 41 g/m(2) with no difference between groups. Mean decrease in LV mass index in the control group was 12 +/- 28 g/m(2) compared to 30 +/- 40 g/m(2) in the candesartan group (p = 0.015) during follow-up. After 12 months LV mass index was significantly lower in the candesartan group (103 +/- 29 vs 119 +/- 31 g/m(2), p = 0.01). In addition, the candesartan group had greater improvement in longitudinal LV systolic function assessed by tissue Doppler S' wave (0.6 +/- 0.1-cm/s increase in control group vs 1.4 +/- 0.1 cm/s in candesartan group, p = 0.01, p for trend = 0.02) and a decrease in LA volume (p for trend = 0.01). Treatment had no effect on diastolic E/e' ratio or B-type natriuretic peptide. In conclusion, angiotensin receptor blockade with candesartan after AVR in patients with AS is associated with augmented reverse LV and LA remodeling compared to conventional management.
Authors:
Jordi S Dahl; Lars Videbaek; Mikael K Poulsen; Patricia A Pellikka; Karsten Veien; Lars Ib Andersen; Torben Haghfelt; Jacob E Møller
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-07-23
Journal Detail:
Title:  The American journal of cardiology     Volume:  106     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-20     Completed Date:  2010-09-28     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  713-9     Citation Subset:  AIM; IM    
Copyright Information:
2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Cardiology, Odense University Hospital, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Aortic Valve Stenosis / complications,  pathology,  therapy*
Benzimidazoles / administration & dosage*
Cohort Studies
Drug Administration Schedule
Female
Heart Valve Prosthesis Implantation*
Humans
Hypertrophy, Left Ventricular / physiopathology,  therapy*,  ultrasonography
Male
Middle Aged
Severity of Illness Index
Tetrazoles / administration & dosage*
Treatment Outcome
Ventricular Remodeling / physiology*
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Tetrazoles; S8Q36MD2XX/candesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Frequency of Conduction Disturbances After Transcatheter Implantation of an Edwards Sapien Aortic Va...
Next Document:  Atrial Arrhythmias in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and Ve...